Zhao Xiantao, Director, Deputy General Manager and Head of China Market at Tuopai Medical
The 18th Frost & Sullivan China Growth, Innovation and Leadership Summit and the 3rd New Investment Conference Life Science New Investment Summit Forum was held in Shanghai from August 28th to 29th, 2024. The forum brought together over 40 industry leaders, biopharmaceutical companies, medical device enterprises, investment institutions and professional service agencies. With the theme of "Responding to Changes and Opening New Horizons", all parties attending the forum jointly explored new models of investment cooperation, aiming to build a closer, more efficient and win-win cooperation network to jointly promote the vigorous development of the domestic and international life science industry.
At this forum, Zhao Xiantao, Director, Deputy General Manager and Head of China Market at Tuopai Medical, delivered a speech on "Innovative Applications of Optoelectronic Technology in Medical Devices", demonstrating the innovative development trend of optoelectronic technology in medical devices, as well as the company's latest achievements and future vision in the field of high-end ophthalmic medical devices.
The key points of Zhao Xiantao's speech are as follows:
Tuopai Overview
The eye is the only organ in the body that can directly observe blood vessels. Besides diseases of the ophthalmology itself, many systemic diseases can be reflected through the fundus. In recent years, domestic enterprises have gradually made efforts in providing high-quality alternatives for domestic ophthalmic medical devices. Tuopai Medical was established in 2017 and is a high-tech enterprise focusing on the research, development and manufacturing of high-end medical devices. The core technology of Tuopai Medical comes from the transformation of Tsinghua's scientific and technological achievements. One of its core competitiveness lies in its independent research and development ability of underlying devices, with a localization rate exceeding 95%. Tuopai Medical closely combines clinical needs. After determining the technical breakthrough points, it conducts research and development on optoelectronic core devices, which can not only provide products with differentiated advantageous functions, ensuring product technology advancement and market competitiveness, but also help change and improve the diagnosis and treatment process and enhance the quality of medical services.
Tuopai's Main Products
As a milestone product in the field of ophthalmic medicine and engineering integration, ophthalmic OCT was initially applied in the United States in the 1990s. Tuopai Medical's OCT product adopts the world-leading full-field scanning technology. "Beiming" has a super-wide-angle OCTA function of 400,000 times, ranking first in the industry's market share for two consecutive years in the domestic market. It is also the first case in China's ophthalmology field where a domestic innovative product has changed the diagnosis and treatment process and promoted guideline innovation. In addition, "Baying" OCT has been successfully sold and applied in dozens of hospitals in Europe one month after obtaining CE certification.
Tuopai Medical's fully digital holographic intraoperative navigation microscope "Duyun" has recently obtained certification. With multi-modal image intelligent navigation technology, it has brought a revolutionary "future model" to ophthalmic surgery. "Duyun" not only retains the high-resolution traditional optical microscopic imaging structure but also realizes real-time intraoperative OCT navigation, reducing surgical difficulty and improving postoperative expectations.
Tuopai Medical's "Zhuozhao" super-wide-angle fundus camera is an intelligent choice for AI eye disease screening. It has an imaging range of 150° super-wide angle and is equipped with four different wavelength lasers, comprehensively covering the retina-choroid.
The market for optical biometers has long been dominated by Zeiss. "Ziwu" biometer, based on maintaining the existing advantages of the Zeiss Master series, has created a unique global "dynamic panoramic visualization" innovation model by applying Tuopai's sufficient underlying technology and resource devices.
Gene therapy is an important development direction for the future treatment of fundus diseases. Tuopai Medical plans to use intraoperative OCT images to link with ophthalmic surgical robots to achieve the delivery of ophthalmic gene therapy drugs.
Zhao Xiantao emphasized in his speech that Tuopai Medical will continue to promote innovation in the integration of medicine and engineering in the field of ophthalmology and achieve technological breakthroughs in domestic high-end ophthalmic medical devices.
